Ditchcarbon
  • Contact
  1. Organizations
  2. Hospira
Public Profile
Research Pending

This profile hasn't yet passed our validation checks

Submit your email to push it up the queue

We'll prioritize this organization's research and notify you when detailed sustainability data becomes available.

Pharmaceutical Preparation Manufacturing
US
updated a month ago

Hospira

Company website

Hospira, Inc., a leading global provider of injectable drugs and infusion technologies, is headquartered in the United States. Founded in 2004, the company has established itself as a key player in the pharmaceutical and biotechnology industry, focusing on critical care and hospital products. With major operational regions across North America, Europe, and Asia, Hospira is renowned for its commitment to quality and innovation. The company offers a diverse range of core products, including sterile injectable medications, biosimilars, and advanced infusion systems, which are distinguished by their reliability and safety features. Hospira's market position is bolstered by its notable achievements in enhancing patient care and streamlining hospital operations, making it a trusted partner in healthcare settings worldwide.

DitchCarbon Score

How does Hospira's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

80

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Hospira's score of 80 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.

89%

Let us know if this data was useful to you

Hospira's reported carbon emissions

Inherited from Pfizer Inc.

Hospira, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family relationship with Pfizer Inc., which influences its climate commitments and initiatives. As a current subsidiary of Pfizer Inc., Hospira's climate strategies and targets are aligned with those of its parent company. Pfizer has set science-based targets (SBTi) to reduce its carbon footprint, which cascades down to Hospira. This includes commitments to renewable energy initiatives and participation in the CDP (formerly Carbon Disclosure Project) to enhance transparency in environmental impact. While specific reduction targets for Hospira are not detailed, the overarching goals from Pfizer aim to significantly lower emissions across all scopes, including Scope 1, 2, and 3. The commitment to sustainability is evident through initiatives like RE100 and the Race to Zero campaign, which further reinforce the company's dedication to addressing climate change. In summary, while Hospira does not provide specific emissions data, it is actively engaged in climate commitments through its affiliation with Pfizer Inc., focusing on reducing its environmental impact in line with industry standards.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2012201320142015201620172018201920202021202220232024
Scope 1
-
-
-
-
-
-
-
-
000,000,000
000,000,000
-
-
-
Scope 2
-
-
-
-
-
-
-
-
000,000,000
000,000,000
-
-
-
Scope 3
-
-
-
-
-
-
-
000,000,000
0,000,000,000
0,000,000,000
000,000,000
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Hospira's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Hospira is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Hospira is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Novartis Pharmaceuticals Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated 24 days ago

Auro Medics Pharma Llc

US
•
Pharmaceutical Preparation Manufacturing
Updated 18 days ago

Teva Pharmaceuticals

IL
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Perrigo

IE
•
Pharmaceutical Preparation Manufacturing
Updated 16 days ago

Baxter

US
•
Medical, precision and optical instruments, watches and clocks (33)
Updated about 2 hours ago

ADVANZ PHARMA Corp. Limited

GB
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251007.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy